Exscientia Expands AWS Partnership to Enhance AI-Driven Drug Discovery

Healthcare Technology Report August 15, 2024

Exscientia has announced an expansion of its collaboration with Amazon Web Services (AWS) to incorporate advanced AI and ML services for its drug discovery platform. This strategic partnership will leverage AWS’s generative AI models and scalable cloud infrastructure to expedite the design and testing of drug candidates. Exscientia’s platform, which includes the DesignStudio and the UK-based AutomationStudio, utilizes generative AI to innovate beyond traditional high-throughput screening methods. By automating the synthesis and testing of molecular designs, Exscientia aims to streamline the drug discovery process, significantly reducing costs and time associated with conventional methods. Data from these processes feeds back into the generative AI algorithms, creating a continuous improvement loop that enhances the precision...

Today's Sponsors

Today's Sponsor